Skip to main content

Peer Review reports

From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

Original Submission
29 Jul 2021 Submitted Original manuscript
12 Sep 2021 Reviewed Reviewer Report - Takaya Shimura
18 Sep 2021 Reviewed Reviewer Report
21 Sep 2021 Reviewed Reviewer Report
16 Nov 2021 Author responded Author comments - Fedor Kryukov
Resubmission - Version 2
16 Nov 2021 Submitted Manuscript version 2
30 Nov 2021 Author responded Author comments - Fedor Kryukov
Resubmission - Version 3
30 Nov 2021 Submitted Manuscript version 3
13 Dec 2021 Reviewed Reviewer Report
15 Dec 2021 Reviewed Reviewer Report
20 Dec 2021 Reviewed Reviewer Report - Takaya Shimura
27 Dec 2021 Author responded Author comments - Fedor Kryukov
Resubmission - Version 4
27 Dec 2021 Submitted Manuscript version 4
12 Jan 2022 Author responded Author comments - Fedor Kryukov
Resubmission - Version 5
12 Jan 2022 Submitted Manuscript version 5
21 Jan 2022 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
24 Jan 2022 Editorially accepted
1 Feb 2022 Article published 10.1186/s12885-022-09243-7

You can find further information about peer review here.

Back to article page